Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
Fiona Day(Calvary Mater Newcastle Hospital), Jarad Martin(Calvary Mater Newcastle Hospital), James Lynam, Joshua Sappiatzer(Flinders Private Hospital), Christopher Oldmeadow(Hunter Medical Research Institute), Gaik Tin Quah(Calvary Mater Newcastle Hospital), Allison Fraser(Calvary Mater Newcastle Hospital), Girish Mallesara(Calvary Mater Newcastle Hospital), Swetha Sridharan(Calvary Mater Newcastle Hospital), André van der Westhuizen(Hunter Medical Research Institute), Amitesh Roy(Flinders Medical Centre), Craig Gedye(Centre for Cancer Biology), Stephen R. Thompson(UNSW Sydney), Michael Michael(Flinders University), Trevor Leong(The University of Melbourne), Hiren Mandaliya(Lake Macquarie Private Hospital), Mahesh Kumar(Calvary Mater Newcastle Hospital), Catherine Johnson(Pfizer (United States))
Cited by 6
Related Papers
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
|Nature Genetics|2018|1.5k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|646
Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders
|The American Journal of Human Genetics|2018|453